-
The loss of the Yushatan storm is serious, can Huahai Pharmaceuticals get out of the difficult situation in 2019?
Time of Update: 2021-03-04
Huahai Pharmaceuticals currently business to specialty raw materials and preparations mainly, raw materials mainly include antihypertensive, psychotic and anti-AIDS and other characteristics of raw m
-
Kaiyu Bio completed tens of millions of yuan of round A financing for the main project preclinical development
Time of Update: 2021-03-04
Kaihe Bio today announced the completion of tens of millions of yuan of round A financing, by Jundudi Investment and Vosseng Capital co-investment.
-
Kill the catcher! ST Changsheng intends to be forced out of the market!
Time of Update: 2021-03-04
According to the China Securities News, from November 8th, st Changsheng staged the "Skyboard", after which seven consecutive trading days, the cumulative turnover amounted to 1.706 billion yuan.
-
The pay of 23 pharmaceutical companies was announced, with Murray the highest
Time of Update: 2021-03-04
It can be seen that, whether for executives or ordinary employees, Murray Medical and Fosun Pharma pay enough generous wages, can be described as the "best employer." ▍ Fosun Pharma: High executive pay, high proportion of research and development It is understood that Fosun Pharma is mainly to drug research and development and manufacturing as the core, at the same time in the pharmaceutical circulation, medical services, medical diagnostics and medical devices and other fields have a high market position.
-
Hebei consolidates and divides by drug supplements to speed up the construction of medical associations
Time of Update: 2021-03-04
same time, Hebei has accelerated the pace of medical association construction, implemented the functional orientation of various medical and health institutions at all levels, promoted inter-agency collaboration, and promoted the sinking of high-quality medical resources.
-
Changchun Gaoxin threw 5.6 billion restructuring commitments to earn nearly 6 billion in three years
Time of Update: 2021-03-04
Data show that Jinsai Pharmaceuticals is mainly engaged in the research and development, production and sales of biopharmaceous products, the main products for injection recombinant human growth hormone, recombinant human growth hormone injection, polyethyl glycol recombinant human growth hormone injection, among which, recombinant human growth hormone injection sales in 2018 more than 2 billion yuan, gross margin of 96.97 percent.
-
Run away from the PD-L1 and the $10 billion double-resistant market Corning Jerry's IPO in Hong Kong today
Time of Update: 2021-03-04
01 Double Resistance Race: Another Upcoming According to the previously disclosed prospecto, Corning Jerry's current product pipeline includes eight tumor candidate drugs, four of which are in the clinical stage, with progress from Clinical Phase I to Critical Phase II/III.
-
Kyushua Pharmaceuticals' $790 million acquisition of Novaral's CDMO subsidiary is on fire!
Time of Update: 2021-03-04
After the acquisition is completed, the company will give full play to Suzhou Novarchi's core business advantages, optimize the company's core business advantages in areas such as innovative drug CDMO one-stop service, and meet China's fast-growing commissioned research and development and production needs, Kyushua Pharmaceuticals said in a statement.
-
High-value consumables new sharp Gligtai received 10 million levels of financing
Time of Update: 2021-03-04
(ligetai) received a new round of 10 million yuan financing, the investors for The Acquisition and Huitong.
This financing will continue to be used for the company's core product development.
-
Comey Pharmaceuticals' finance director was heavily fined
Time of Update: 2021-03-04
Specifically, there are several major points: First, imitation, transformation of VAT invoices and other ways to inflate operating income between 2016 and 2018, Kangmei Pharmaceuticals is suspected of falsifying, changing VAT invoices and other ways to inflate operating income, through counterfeiting, transformation of large periodic deposit slips and other ways to inflate monetary funds, will not meet accounting confirmation and measurement conditions of engineering projects into the report, false increase in fixed assets.
-
Generic drugs will accelerate the replacement of the original research drug high-quality generic drug companies to benefit
Time of Update: 2021-03-04
According to estimates by the China Pharmaceutical Industry Information Center, China's patent expired original research drug market size reached 141.9 billion yuan, accounting for about 14.23 percent of the overall size of chemical and biological drugs, by 2025 China will have 48 imported chemical drug varieties core patents due.
-
A batch of ointments was exposed to strictly check the sale of non-drugs in pharmacies
Time of Update: 2021-03-04
It is reported that the Gusu District Market Supervision Bureau, after receiving the inspection recommendations, for retail pharmacies to carry out a special rectification activities.
-
Sansheng Pharmaceuticals' first half 2019 results were announced
Time of Update: 2021-03-04
have also made significant progress: humanized anti-tumor necrotizing factors α anti-tumor necrotizing factors for patients with rheumatoid arthritis (RA) α antibody products (SSS07) have completed health volunteers and RA The first phase of clinical trials in patients is currently preparing for the second phase trial of RA patients and other inflammatory diseases, and the clinical trial of anti-IL-17A antibodies (608) for moderate-severe plaque-like psoriasis was approved by the National Drug Administration on July 31 this year.
-
Soryuan Bio signed a licensing agreement to develop DB102 new adaptations
Time of Update: 2021-03-04
, , December 26, 2019 - Precision Medicine leader So yuan Bio today announced that it has signed a licensing agreement with Rumpus Therapeutics to develop DB102 for the treatment of specific adaptive disorders.
-
Baiji Shenzhou's latest response: The allegations in the short report are blatantly false
Time of Update: 2021-03-04
Capital Research, a capital research firm, released a report saying that Baiji state may have "faked" sales.
Notably, Baiji Shenzhou has not responded to seven questions in the short report of J.Capital Research, a capital research firm.
-
Chongqing Pharma acquired an 87.47% stake in the subsidiary
Time of Update: 2021-03-04
On December 16, Tiansli announced that it had signed a Framework Agreement with Chongqing Pharmaceuticals (Group) Co., Ltd.
("Chongqing Pharmaceuticals") to sell its controlling subsidiary, Tianjin Tiansli Pharmaceutical Marketing Group Co., Ltd.
-
Ningbo test water doctor title can go up and down
Time of Update: 2021-03-04
It is understood that Ningbo City, the first hospital's original compensation mechanism is divided into professional and technical posts into junior, intermediate, vice-high, positive high 4 categories of 13 grades, the implementation of the separation of evaluation and employment, each level of corresponding pay is different, reflecting the value of labor services is not obvious.
-
Dr. Meng Pharmaceuticals new retail into the industry benchmark, into more than 2000 hospitals
Time of Update: 2021-03-04
To innovative new health technology to help smart hospitals move forward Dr. Meng is the leading mobile medical brand in China, covering mobile medical, pharmaceutical e-commerce, new retail, drugstore chains and other sectors.
-
Innovative medicine blows! Hengrui's half-year revenue of 10 billion Chinese biopharmaceuticals 12.5 billion
Time of Update: 2021-03-04
In fact, as the largest pharmaceutical company by market capitalization in China, Hengrui Pharmaceuticals has also begun to shift its research and development focus to innovative pharmaceuticals, according to the semi-annual report, in the first half of 2019 Hengrui Pharmaceuticals invested 1,484 million yuan in research and development, an increase of 49.13 percent over the same period last year, and the proportion of research and development investment in sales revenue reached 14.80 percent.
-
Haizheng Pharmaceuticals gave a controlling stake in its subsidiary of $3.828 billion or eased its $10 billion debt
Time of Update: 2021-03-04
Recently, Haizheng Pharmaceuticals announced that the Taiwan Stock Exchange confirmed the delisting of Taizheng Investment Group (one of Asia's largest independent alternative investment management g
